Bitter melon Momordica charantia L.
Also called: bitter gourd, balsam pear, goya, bitter squash
Bitter melon is a climbing vine of tropical and subtropical regions with a ridged, warty, very bitter fruit eaten raw, cooked or in teas. Supplements, sold as liquids, powders and tablets, mainly use fruit extracts; preparations of other parts, including leaf, have been studied.
- Category
- Botanical
- Part used
- Fruit (extracts, powders); some preparations use leaf
- Strongest evidence
- B Some positive trials
- Native range
- Native to the tropical and subtropical Old World to the South Pacific (POWO: "Trop. & Subtrop. Old World to S. Pacific")
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2024 systematic review and meta-analysis pooled nine randomized placebo-controlled trials (414 patients) of Momordica charantia fruit mono-herbal preparations; a 2012 Cochrane review included four RCTs (479 participants). [5]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBlood sugar and weight5 topics
BHeart and blood vessels1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood sugar control in type 2 diabetes (Cochrane review) | C | A 2012 Cochrane review of four RCTs (479 participants, up to 3 months, generally high risk of bias) found no significant difference in glycemic control versus placebo, metformin or glibenclamide and called the evidence insufficient. [3] |
| Blood sugar control in type 2 diabetes (2019 meta-analysis) | B | A 2019 meta-analysis of 10 studies (1,045 patients, 4–16 weeks) found single-herb preparations lowered fasting glucose (-0.72 mmol/L) and HbA1c (-0.26%) versus placebo; evidence was rated low to very low quality. [4] |
| Metabolic syndrome measures (2024 meta-analysis) | C | A 2024 meta-analysis of nine RCTs (414 patients, 4–16 weeks) found no significant effect versus placebo on fasting glucose, HbA1c, lipids, body weight or blood pressure; statistical power was low. [5] |
| Glucose and insulin resistance in prediabetes and type 2 diabetes (2025 meta-analysis) | B | A 2025 meta-analysis of 25 RCTs (34 sub-studies) reported lower fasting glucose (SMD -0.46), HbA1c (SMD -0.57), insulin and HOMA-IR, with no effect on HOMA-beta. [6] |
| Blood lipids | B | A 2024 meta-analysis of eight RCTs (423 participants) found lower total cholesterol (-9.71 mg/dL) and triglycerides (-10.24 mg/dL), with no significant change in LDL or HDL cholesterol; trials were shorter than 3 months. [7] |
| Body weight and body composition | C | A 2024 meta-analysis of 10 trials (448 participants) found no significant change in body weight, BMI, waist circumference or percentage body fat. [8] |
Main constituents: Alkaloids, glycosides, saponins, triterpenes, oils, steroids/sterols, polysaccharides, resins and proteins; the hypoglycemic component has not been identified [1]; Momordicosides and momordicines (linked to bitterness), ribosome-inactivating proteins; seeds contain vicine [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Trials in a meta-analysis cited by LiverTox used 2 to 6 g daily for 4 to 16 weeks; individual trials used 3 g daily for 3 months, 500, 1,000 or 2,000 mg daily for 4 weeks, and 2,380 mg daily for 12 weeks. [1]
- LiverTox states a typical recommended dose of 500 to 1,000 mg taken two to three times daily. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated March 20, 2023).
Details and sources - Pregnancy and breastfeedingLiverTox: bitter melon is a potential abortifacient and should not be used during pregnancy or by women of childbearing age who are not using …
2 statements in the profile.
Details and sources - Interactions with medicines3 listed
Insulin and other blood-sugar-lowering drugs; P-glycoprotein substrates (such as vinblastine and paclitaxel); CYP2C9 substrates
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Bitter melon is a potential abortifacient; LiverTox states it should not be used during pregnancy or by women of childbearing age not using effective contraception. [1]
- Side effects include abdominal discomfort, heartburn, constipation or diarrhea, nausea, vomiting, dizziness, headache and hypoglycemia; rare but severe effects include severe hypoglycemia, coma and seizures. [1]
- LiverTox likelihood score E (unlikely cause of clinically apparent liver injury); no published cases of liver injury attributable to bitter melon extracts (chapter updated March 20, 2023). [1]
- Seeds contain vicine, linked to favism-like toxicity with headache, fever, abdominal pain and coma. [2]
- Case reports describe atrial fibrillation, acute gastric ulceration after about half a liter of homemade extract, and acute interstitial nephritis or severe kidney injury. [2]
Interactions
| With | What happens |
|---|---|
| Insulin and other blood-sugar-lowering drugs | MSK: possible additive effect. [2] |
| P-glycoprotein substrates (such as vinblastine and paclitaxel) | MSK: may increase drug concentration and toxicity; clinical significance undetermined. [2] |
| CYP2C9 substrates | MSK: bitter melon extract inhibits CYP2C9, which may alter metabolism of some drugs; clinical significance undetermined. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- In the Cochrane review no similar preparation was tested twice; the authors called for standardization and quality control of preparations. [3]
Regulatory status
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Alkaloids, glycosides, saponins, triterpenes, oils, steroids/sterols, polysaccharides, resins and proteins (LiverTox: the hypoglycemic component has not been identified) Mixed classes (alkaloids, saponins, terpenoids, polysaccharides, proteins) [P1]
- Vicine in the seeds, linked to favism-like toxicity Glycoside (PubChem CID 135413566 describes vicine as a glycoside) [P2]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 3 entries naming Momordica charantia (earliest NDI 138 submitted 2002-02-11; most recent NDI 231 submitted 2003-05-06, a combination with Cordyceps sinensis extract). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of bitter melon (Momordica charantia) was found (IARC Monographs list of classifications, Volumes 1–142, and NTP technical reports checked 2026-10-29). [P5]
- The NTP Technical Reports index (TR-001 to TR-606) lists no study of bitter melon or Momordica (checked 2026-10-29). [P6]
Liver (NIH LiverTox)
- LiverTox likelihood score E: unlikely cause of clinically apparent liver injury (chapter last updated March 20, 2023). No published reports of serum enzyme elevations or clinically apparent liver injury attributable to bitter melon extracts; most trials showed no change or slight improvement in aminotransferases. [P1]
Interactions with medicines
- Insulin and other blood-sugar-lowering drugs: MSK: possible additive effect. [P2]
- P-glycoprotein substrates (such as vinblastine and paclitaxel): MSK: may increase drug concentration and toxicity; clinical significance undetermined. [P2]
- CYP2C9 substrates: MSK: bitter melon extract inhibits CYP2C9, which may alter metabolism of some drugs; clinical significance undetermined. [P2]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; a firm may petition FDA for an exemption under 111.75(a)(1)(ii). [P7]
Supply and conservation
- GBIF species API returns IUCN category Not Evaluated (NE) for Momordica charantia L., retrieved 2026-10-29. [P8]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Sources for this profile
- NIH LiverTox (NIDDK). Bitter Melon (Last Update: March 20, 2023), 2023-03-20. ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Bitter Melon (Last Updated December 22, 2021), 2021-12-22. mskcc.org
- PubChem. Vicine, CID 135413566: description (retrieved 2026-10-29), 2026-10-29. pubchem.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications, Volumes 1–142 (retrieved 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; retrieved 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Momordica charantia L., 2026-10-29. api.gbif.org
Sources
- NIH LiverTox (NIDDK). Bitter Melon (Last Update: March 20, 2023), 2023-03-20. ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Bitter Melon (Last Updated December 22, 2021), 2021-12-22. mskcc.org
- Ooi CP, Yassin Z, Hamid TA. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012;(8):CD007845 (PMID 22895968), 2012-08-15. pubmed.ncbi.nlm.nih.gov
- Peter EL, et al. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: systematic review and meta-analysis. J Ethnopharmacol 2019;231:311-324 (PMID 30385422), 2019-03. pubmed.ncbi.nlm.nih.gov
- Laczkó-Zöld E, et al. The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials. Front Nutr 2024;10:1200801 (PMID 38274207), 2024-01. pubmed.ncbi.nlm.nih.gov
- Mkhize SAL, et al. Efficacy of Momordica charantia in glycaemic control and insulin resistance among patients with prediabetes and type 2 diabetes: a GRADE-adherent meta-analysis of randomised controlled trials. Metabol Open 2025;28:100407 (PMID 41280283), 2025-10. pubmed.ncbi.nlm.nih.gov
- Amini MR, et al. The effects of bitter melon (Momordica charantia) on lipid profile: a systematic review and meta-analysis of randomized controlled trials. Phytother Res 2024;38(12):5949-5961 (PMID 39444254), 2024-12. pubmed.ncbi.nlm.nih.gov
- Zou Y, et al. The effects of bitter melon (Momordica charantia) on anthropometric indices in adults: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Other Lipid Mediat 2024;174:106877 (PMID 39079610), 2024-10. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Momordica charantia L. (accessed 2026-10-29; native range: "Trop. & Subtrop. Old World to S. Pacific"), 2026-10-29. powo.science.kew.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.